Medical Advocates
Indinavir (Crixivan)
 
Journal Citations: Adverse
Events

General Reports
 Buffalo Hump        
Facial Atrophy  
 Hyperbilirubinemia
 Photophobia                     
Renal/Urinary Disorders
 Other Adverse Events


 
Journal Main Page Main New/Newsworthy  Home Page      
Last Update:  August 21, 2015
Documents identified with this icon are in Portable Document Format (PDF) and require the  Adobe Acrobat Reader 5 .
Perinatal Journal Data are integrated with Perinatal Conference Data in the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric  Conference Data in the Pediatric Data Page
General Reports
       
 
Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-
related toxicity.
 Wasmuth JC, Lambertz I, Voigt E, et al
Eur J Clin Pharmacol. 2007 Aug 10;
 Abstract
 
Indinavir impairs endothelial function in healthy HIV-negative men.
 Shankar SS, Dube MP, Gorski JC, et al   
 Am Heart J. 2005 Nov;150(5):933.e1-933.e7.
Abstract

Dose reduction for the management of indinavir-related toxicity in human
immunodeficiency virus type 1-infected patients in Taiwan: clinical and
pharmacokinetic assessment.
 Pan SC, Hsieh SM, Hung CC, Huang PF, Chen MY, Chang SC.  
 J Microbiol Immunol Infect. 2005 Feb;38(1):31-4
 Abstract

  
Buffalo Hump
       
  "Buffalo hump" related to indinavir treatment
 Dornier C, Posth M, Granel F, et al
Ann Dermatol Venereol 1999 Oct;126(10):720-2
 Abstract		  
Facial Atrophy
       
  Indinavir-associated facial lipodystrophy in HIV-infected patients.
Ho TT, Chan KC, Wong KH, Lee SS.
AIDS Patient Care STDS 1999 Jan;13(1):11-6
 Abstract		  
Hyperbilirubinemia    
       
  Photophobia in a patient with high indinavir plasma concentrations.
Huitema AD, Kuiper RA, Meenhorst PL
Ther Drug Monit. 2003 Dec;25(6):735-7.
 Abstract
 
FULL-TEXT ARTICLE
 Mechanism of indinavir-induced hyperbilirubinemia.
Zucker SD, Qin X, Rouster SD, et al.  
 Proc Natl Acad Sci U S A 2001  Oct 16
 Paper
Photophobia
       
  Photophobia in a patient with high indinavir plasma concentrations.
Huitema AD, Kuiper RA, Meenhorst PL
Ther Drug Monit. 2003 Dec;25(6):735-7.
 Abstract
Renal/Urinary Disorders
       
 
Indinavir-induced nephrolithiasis three and one-half years after cessation
of indinavir therapy.
Huynh J, Hever A, Tom T, Sim JJ.  
Int Urol Nephrol. 2010 May 11.
 Abstract

Indinavir-associated tubulointerstitial renal disease.
 Gagnon RF, Mehio A, Iqbal S, Tsoukas CM .
Nephrol Ther. 2007 Dec;3(7):461-462.
 Abstract
 
Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected
Adults.
Collin F, Chene G, Retout S, et al 
Ther Drug Monit. 2007 Apr;29(2):164-170
 Abstract
 
Urological management of indinavir-associated acute renal failure in HIV-positive patients.
 Kalaitzis C, Passadakis P, Giannakopoulos S, et al 
Int Urol Nephrol. 2006 Dec 19;
 Abstract
 
Urinary NO3 excretion and renal failure in indinavir-treated patients.
 Eira M, Araujo M, Seguro AC. 
Braz J Med Biol Res. 2006 Aug;39(8):1065-70
 Abstract
 
The use of pharmacokinetically guided indinavir dose reductions in the management of
indinavir-associated renal toxicity.
 Boyd MA, Siangphoe U, Ruxrungtham K, et al 
J Antimicrob Chemother. 2006 Apr 4;
 Abstract
 
Indinavir Urolithiasis
Kalaitzis C, Touloupidis S, Patris E, et al
 Urologe A. 2004 Feb;43(2):168-71
 Abstract
 
Persistent Leukocyturia and Loss of Renal Function in a Prospectively Monitored C
ohort of HIV-Infected Patients Treated with Indinavir  
 Dieleman JP,  van Rossum AMC,   Stricker BCH, et al
 JAIDS  2003; 32(2):135-142
Abstract

Indinavir-induced retinoid-like effects: incidence, clinical features and management.
Garcia-Silva J, Almagro M, Pena-Penabad C, Fonseca E.
 Drug Saf. 2002;25(14):993-1003.
 Abstract

Risk factors for indinavir-related renal colic in HIV patients: predictive value of indinavir
dose/body mass index.
Meraviglia P, Angeli E, Del Sorbo F 
AIDS 2002 Oct 18;16(15):2089-93
 Abstract

Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease
Inhibitor Indinavir Sulfate: The ATHENA Cohort.
 Dieleman JP, Sturkenboom MC, Jambroes M, et al
 Arch Intern Med 2002 Jul 8;162(13):1493-501
 Abstract

Urinary cytology associated with human polyomavirus and indinavir therapy in |
HIV-infected patients.
Filie AC, Wilder AM, Brosky K
Am J Clin Pathol 2002 Jun;117(6):922-6
Abstract

Indinavir-associated interstitial nephritis and urothelial  inflammation: clinical and
cytologic findings.
Kopp JB, Falloon J, Filie A,  et al.
Clin Infect Dis 2002 Apr 15;34(8):1122-8 
Abstract   

Indinavir nephropathy revisited: a pattern of insidious renal failure with identifiable
risk factors.
Reilly RF Tray K, Perazella MA.
Am J Kidney Dis 2001 Oct;38(4):E23
 Abstract
Incidence and risk factors for the development of indinavir-associated renal complications.
 Herman JS, Ives NJ, Nelson M, et al
 J Antimicrob Chemother 2001 Sep;48(3):355-60\
 Abstract

 		 
Other Adverse Events
       
 
Indinavir-associated toxicity mimicking urinary tuberculosis in a patient with AIDS.
Delfino VD, Santiago NM, Mocelin AJ, et al
Braz J Infect Dis. 2008 Feb;12(1):99-100.
 Abstract

Persistent Leukocyturia and Loss of Renal Function in a Prospectively Monitored Cohort of
HIV-Infected Patients Treated with Indinavir  
Dieleman JP,  van Rossum AMC,   Stricker BCH, et al
JAIDS  2003; 32(2):135-142
Abstract

Indinavir-induced cholelithiasis in a patient infected with human immunodeficiency virus.
Verdon R, Daudon M, Albessard F, et al.
 Clin Infect Dis 2002 Sep 1;35(5):e57-9
Abstract

Indinavir did not increase the short-term risk of adverse cardiovascular events relative to
nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials.
Coplan PM, Nikas AA, Leavitt RY, Doll L, et al.  
 AIDS 2001 Aug 17;15(12):1584-6
 Abstract

Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive
crisis: a case report.
 Giner V, Fernandez C, Esteban MJ, et al.
Am J Hypertens 2002 May;15(5):465-7  
Abstract

 Rheumatological complications associated with the use of indinavir and other protease
inhibitors.
 Florence E, Schrooten W, Verdonck K,
Ann Rheum Dis 2002 Jan;61(1):82-4  
Abstract 

Papillary necrosis associated with the HIV protease inhibitor indinavir.
Dieleman JP, van der Feltz M, Bangma CH, et al.
Infection 2001 Aug;29(4):232-233
Abstract

Recurrent ingrown toenails secondary to indinavir/ritonavir combination therapy.
James CW, McNelis KC, Cohen DM , et al.
Ann Pharmacother 2001 Jul-Aug;35(7-8):881-4
 Abstract
Stable or increasing bone mineral density in HIV-infected patients treated with
nelfinavir or indinavir.
Nolan D, Upton R, McKinnon E, et al.
AIDS 2001 Jul 6;15(10):1275-80
 Abstract

Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity
and B-cell function in HIV-infected patients.
Dube MP, Edmondson-Melancon H, Qian D, et al.
J Acquir Immune Defic Syndr 2001 Jun 1;27(2):130-4
 Abstract

  

Journal Main Page Main New/Newsworthy  Home Page      

Indinavir Journal Citations: Adverse Events